70 patients | |
---|---|
Age at diagnosis, mean ± SD (range) | 46 ± 11 years (26–79) |
Relatives with breast cancer, mean ± SD (range) | 4.1 ± 1.5 (1–9) |
Histology | |
- Ductal carcinoma | 84% |
- Medullary carcinoma or medullary-like | 4% |
- Other invasive carcinomas | 8% |
- Ductal in situ carcinoma | 4% |
Grade | |
- Grade 1 | 13% |
- Grade 2 | 55% |
- Grade 3 | 27% |
- Missing | 5% |
Size, median (range) | 17 mm (2–115) |
Ki67, median (range) | 20% (5–80) |
Estrogen receptor + | 75% |
Molecular classification | |
- Luminal (A - B - ERBB2+) | 52% (15% - 34% - 16%) |
- ER− ERBB2+ | 3% |
- Triple-negative | 13% |
- ERBB2 status missing | 19% |
Positive lymph nodes | 34% |
2nd breast cancer (of which contralateral) | 34% (81%) |
Breast cancer lifetime residual risk, mean ± SD (range) | 15 ± 7% (2–30)—26 NA |
BRCA mutation carrier pre-test probability, median (range) | 13% (1–91) |